Alector/ALEC

$7.00

-0.14%
-
1D1W1MYTD1YMAX

About Alector

Alector, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on immuno-neurology, a therapeutic approach for the treatment of neurodegenerative diseases. The Company is engaged in developing therapies designed to counteract these pathologies by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its clinical programs include AL001 (latozinemab), AL101, and AL002. In addition, the Company also focuses on preclinical and research programs in its pipeline for indications, including Alzheimer’s disease, Parkinson’s disease, and oncology. Its first product candidate, latozinemab, is a humanized recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of frontotemporal dementia carrying a progranulin (FTD-GRN) patients.

Ticker

ALEC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Arnon Rosenthal

Employees

246

Headquarters

South san francisco, United States

Alector Metrics

BasicAdvanced
$615.64M
Market cap
-
P/E ratio
-$1.70
EPS
0.79
Beta
-
Dividend rate

What the Analysts think about Alector

Analyst Ratings

Majority rating from 12 analysts.
Buy

Price Targets

Average projection from 9 analysts.
103.14% upside
High $41.00
Low $4.00
$7.00
Current price
$14.22
Average price target

Alector Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-487.91% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$9.1M
-83.81%
Net income
$-44.4M
-3,515.38%
Profit margin
-487.91%
-21,221.65%

Alector Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 36.44%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.55
$0.02
-$0.53
-$0.49
-
Expected
-$0.76
-$0.82
-$0.66
-$0.77
-$0.71
Surprise
-27.54%
-102.44%
-19.36%
-36.44%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Alector stock

Buy or sell Alector stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing